Clinical Guideline Review
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Author(s): Cindy Neunert, Deirdra R. Terrell, Donald M. Arnold, George Buchanan, Douglas B. Cines, Nichola Cooper, Adam Cuker, Jenny M. Despotovic, James N. George, Rachael F. Grace, Thomas K¨ uhne, David J. Kuter, Wendy Lim, Keith R. McCrae, Barbara Pruitt, Hayley Shimanek, and Sara K. Vesely
DATE OF PUBLICATION: DECEMBER 2019 | DATE OF REVIEW: NOVEMBER 10, 2020
Citation: Blood Advances 10 December, 2019 Volume 3, Number 23, 3829-3866
Method of Review: A subcommittee of the Evidence-Based Practice and Research Committee of the Association of Pediatric Hematology/Oncology Nurses conducted a group review of the clinical recommendations using the AGREE II criteria1. The committee had an overall assessment of approval for endorsement.
Review Summary: These are extremely high-quality guidelines. They are comprehensive and complex guidelines., but the organization of the document allows clinicians to easily find specific recommendations. Pediatric recommendations are clearly highlighted and were developed independently of the adult recommendations. The guidelines would have been better developed if nursing had been involved in the entire process of development. Most of the recommendations are based on very low level and grade evidence, but the guidelines are important to the clinical practice of pediatric hematology. Local adaptation of these guidelines will be necessary in many circumstances. Any adaptations should be based on the Evidence to Development (EtD) frameworks which are part of the guideline publication.
Recommendation for Use: Recommend for use in pediatric hematology..
1AGREE Next Steps Consortium (2009). The AGREE II Instrument [Electronic version]. Retrieved May 2018, from www.agreetrust.org